Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Novartis Mayo Clinic |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00277550 |
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia
Condition | Intervention | Phase |
---|---|---|
Constipation and Dyspepsia |
Drug: Tegaserod and Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Pharmacodynamics Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effects of Tegaserod (6 Mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia |
Estimated Enrollment: | 64 |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients must present with two or more of the following criteria for chronic constipation for at least 12 weeks prior to entering the study:
Exclusion Criteria:
Evidence of cathartic colon or a history of laxative abuse
Study ID Numbers: | CHTF919EUS42 |
Study First Received: | January 13, 2006 |
Last Updated: | September 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00277550 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Constipation, Tegaserod, Dyspepsia |
Serotonin Agonists Signs and Symptoms Neurotransmitter Agents Signs and Symptoms, Digestive |
Constipation Dyspepsia Serotonin Tegaserod |
Serotonin Agonists Signs and Symptoms Neurotransmitter Agents Serotonin Agents Molecular Mechanisms of Pharmacological Action Signs and Symptoms, Digestive |
Physiological Effects of Drugs Constipation Dyspepsia Pharmacologic Actions Tegaserod |